Frank Rimerman Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$355K Sell
570
-432
-43% -$294K 0.02% 483
2026
Q1
$774K Sell
1,002
-3
-0.3% -$2.3K 0.05% 294
2025
Q4
$776K Buy
1,005
+438
+77% +$297K 0.05% 287
2025
Q3
$319K Sell
567
-414
-42% -$234K 0.02% 469
2025
Q2
$515K Buy
981
+67
+7% +$37.4K 0.03% 343
2025
Q1
$580K Buy
914
+390
+74% +$268K 0.05% 286
2024
Q4
$373K Sell
524
-73
-12% -$61.3K 0.03% 370
2024
Q3
$628K Buy
597
+20
+3% +$22.3K 0.04% 291
2024
Q2
$606K Buy
577
+574
+19,133% +$556K 0.04% 302
2024
Q1
$2.89K Hold
3
﹤0.01% 255
2023
Q4
$2.63K Buy
+3
New +$2.47K ﹤0.01% 249

Other funds holding REGN

Frank Rimerman Advisors's REGN Position: Q2 2026 in Review

Frank Rimerman Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 43% in Q2 2026, selling an estimated $294K and leaving 570 shares worth $355K. The position accounts for 0.02% of the portfolio, ranked #483.

Frank Rimerman Advisors first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $776K in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Frank Rimerman Advisors held 570 shares of Regeneron Pharmaceuticals worth $355K as of Q2 2026.
  • Frank Rimerman Advisors sold 432 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $294K.
  • Regeneron Pharmaceuticals made up 0.02% of Frank Rimerman Advisors's portfolio in Q2 2026, its #483 holding.
  • Frank Rimerman Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Frank Rimerman Advisors's Regeneron Pharmaceuticals position peaked at $776K in Q4 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.